GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Neurotech International Ltd (ASX:NTI) » Definitions » Cash Conversion Cycle

Neurotech International (ASX:NTI) Cash Conversion Cycle : 6,083.34 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Neurotech International Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Neurotech International's Days Sales Outstanding for the six months ended in Dec. 2023 was 53198.75.
Neurotech International's Days Inventory for the six months ended in Dec. 2023 was 486.67.
Neurotech International's Days Payable for the six months ended in Dec. 2023 was 47602.08.
Therefore, Neurotech International's Cash Conversion Cycle (CCC) for the six months ended in Dec. 2023 was 6,083.34.


Neurotech International Cash Conversion Cycle Historical Data

The historical data trend for Neurotech International's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurotech International Cash Conversion Cycle Chart

Neurotech International Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Conversion Cycle
Get a 7-Day Free Trial 10.69 -2,359.43 248.06 -2,476.46 -

Neurotech International Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -44,505.29 -1,811.58 -10,554.58 15,999.17 6,083.34

Competitive Comparison of Neurotech International's Cash Conversion Cycle

For the Medical Devices subindustry, Neurotech International's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurotech International's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neurotech International's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Neurotech International's Cash Conversion Cycle falls into.



Neurotech International Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Neurotech International's Cash Conversion Cycle for the fiscal year that ended in Jun. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=0+0-0
=0.00

Neurotech International's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=53198.75+486.67-47602.08
=6,083.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neurotech International  (ASX:NTI) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Neurotech International Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Neurotech International's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurotech International (ASX:NTI) Business Description

Traded in Other Exchanges
N/A
Address
145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009
Neurotech International Ltd is a medical device and solutions company. It researches, designs, markets, and produces wearable neurotechnology devices to assist with neurological conditions such as autism. Geographically, all the business activities of the firm function through the region of Australia. It operates in one segment named Medical Device Development and Distribution.

Neurotech International (ASX:NTI) Headlines

From GuruFocus

9 Stocks With Yields Over 10% And Buy Or Better Rating

By Dividend Dividend 08-17-2013

20 Stocks with Yields over 10% and Highest Buy Ratings

By Dividend Dividend 01-17-2013

How to Capitalize on the Bakken Oil Boom

By Vitaliy Katsenelson Vitaliy Katsenelson 11-09-2013

13 Stocks With Dividend Yields Over 10%

By Dividend Dividend 11-12-2014